Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.
Frequently asked questions
What sector does Theralase Technologies Inc. (TLTFF) operate in?
Theralase Technologies Inc. belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Theralase Technologies Inc. (TLTFF) current stock price?
As of the latest data, Theralase Technologies Inc. stock price is $0.15, with a previous close of $0.15.
What is Theralase Technologies Inc. (TLTFF) current market capitalization?
Theralase Technologies Inc. market cap is approximately 46.57 million.
What is Theralase Technologies Inc. (TLTFF) Earnings Per Share (EPS)?
The trailing EPS is -$0.01.
What is Theralase Technologies Inc. (TLTFF) EBITDA?
Theralase Technologies Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -702.95 thousand.
Does Theralase Technologies Inc. (TLTFF) pay dividends?
No. Theralase Technologies Inc. does not pay a dividend.
What is Theralase Technologies Inc. (TLTFF) beta (volatility) score?
Theralase Technologies Inc. has a beta of 0.411, indicating lower volatility than the overall market.
